Our NK cell-derived extracellular vesicles (EVs) are to be delivered intranasally, a non-invasive approach designed to directly access the brain and overcome limitations of current therapies.
About Evinco Therapeutics
Evinco Therapeutics Pty Ltd is a privately held biotechnology company, based in Melbourne, Australia, developing innovative immune-based therapies for neurological disorders. The Company is focused on advancing NK cell-derived extracellular vesicles (EVs) for the treatment of Alzheimer’s disease and neurological conditions. By pursuing innovative intranasal delivery methods for its NK-EV technology, Evinco aims to offer a safer and more accessible treatment that has the potential to significantly improve the lives of those affected by Alzheimer’s disease and related disorders. Evinco Therapeutics is a subsidiary of Cartherics Pty Ltd..
Our Mission and Vision
Our mission is to generate an effective therapy for Alzheimer’s disease and related neurological conditions through innovative developments in immune biology and targeted therapies.
Our vision is to recover those lost memories.
Subscribe to our Newsletter
Subscribe to our mailing list to receive the latest company updates, news, and announcements straight to your inbox.